Biopharma's biggest sellers – the oldies that just keep giving

Enbrel's recent US patent win has ensured a further eight years of exclusivity for the rheumatoid arthritis treatment. Amgen's biological had already secured its place in biopharma's hall of fame as the fourth biggest selling drug of all time to date, and currently stands to be the third biggest product looking as far ahead as 2024, according to EvaluatePharma consensus.